Original source by EINPresswire. MIAMI -22 September 2026- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other …
Copyright © CB Herald. 2026
